Compare RLX Technology Inc (RLX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Sanofi SA — how do they compare? RLX Technology Inc trades at $2.03 (market cap $2.52B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 41.6× RLX Technology Inc's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| RLX | SNY | |
|---|---|---|
Market Cap | $2.52B | $104.83B |
Sector | Technology | Health |
52-Week High | $2.73 | $52.34 |
52-Week Low | $1.79 | $41.33 |
Enterprise Value | $1.15B | $121.32B |
Dividend Yield | 4.85% | 5.5% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
